Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Abdul-Hamid Bazarbachi, Myriam Labopin, Anna Maria Raiola, Didier Blaise, William Arcese, Stella Santarone, Yener Koc, Stefania Bramanti, Alexander Kulagin, Mi Kwon, Simona Sica, Jaime Sanz, Eolia Brissot, Arnon Nagler, Fabio Ciceri, Mohamad Mohty
BACKGROUND: The optimal choice for graft-versus-host disease (GVHD) prophylaxis in haploidentical stem cell transplantation (haplo-SCT) remains debatable. Posttransplant cyclophosphamide (PTCy) and anti-thymocyte globulin (ATG) are two common strategies, but little is known about their combination. METHODS: Using the European Society for Blood and Marrow Transplantation (EBMT) registry, the authors identified 3649 adult patients with acute myeloid leukemia (AML) who underwent haplo-SCT in complete remission between 2007 and 2021 at 260 EBMT-participating centers who received either PTCy (n = 2999), ATG (n = 358), or combination prophylaxis (n = 292)...
May 17, 2024: Cancer
#2
REVIEW
Christopher Graham, Mark Litzow
INTRODUCTION: The likelihood of finding HLA-matched unrelated donors for rare HLA types and non-white European ancestry continues to be a challenge with less than a 70% chance of finding a full match. Mismatched transplants continue to have high rates of transplant-related mortality. With the near-universal ability to find a haploidentical donor in families, haploidentical transplants have become of more critical importance in ethnic minority groups and patients with rare HLA types. METHODS: Data was collected through clinical trials, review articles, and case reports published in the National Library of Medicine...
December 2024: Hematology (Amsterdam, Netherlands)
#3
JOURNAL ARTICLE
Yukinori Nakamura, Yoshitaka Zaimoku, Hiroki Yamaguchi, Hirohito Yamazaki, Minoru Kanaya, Naoyuki Uchida, Noriko Doki, Masatoshi Sakurai, Nobuhiro Hiramoto, Shinichi Kako, Makoto Onizuka, Koichi Onodera, Yumiko Maruyama, Hiroyuki Ohigashi, Tetsuya Nishida, Satoshi Yoshihara, Ken-Ichi Matsuoka, Tetsuya Eto, Yoshinobu Kanda, Takahiro Fukuda, Yoshiko Atsuta, Yasushi Onishi
The impact of absolute neutrophil count (ANC) before allogenic hematopoietic stem cell transplantation (HSCT) on the outcomes for patients with aplastic anemia (AA) remains unclear. We retrospectively evaluated the relationship between ANC before transplantation and patient outcomes, involving 883 adult Japanese patients with AA who underwent allogeneic HSCT as their first transplantation between 2008 and 2020. Patients were divided into three groups based on ANC: 0/µL (n = 116); 1-199 (n = 210); and ≥ 200 (n = 557)...
May 16, 2024: Annals of Hematology
#4
JOURNAL ARTICLE
Jessica Laue, Johanna Ambühl, Daniel Surbek
BACKGROUND: The increasing demand for umbilical cord blood (UCB) used in stem cell transplantation led to the establishment of cord blood (CB) banks worldwide. These include public foreign donor banks and private family-directed donor banks. Recently, our department has introduced a third banking model within a private-public-partnership. This hybrid banking allows for storage of family-directed CB units, while also getting Human leukocyte antigen (HLA)-typed and included in the national stem cell donor registry...
May 15, 2024: Transfusion
#5
JOURNAL ARTICLE
Mayumi Iwatake, Tokiko Nagamura-Inoue, Ryoichiro Doi, Yukinori Tanoue, Mitsutoshi Ishii, Hiroshi Yukawa, Keitaro Matsumoto, Koichi Tomoshige, Takeshi Nagayasu, Tomoshi Tsuchiya
BACKGROUND: Researchers are focusing on cellular therapy for chronic obstructive pulmonary disease (COPD) using mesenchymal stem cells (MSCs), with human bone marrow-derived MSCs (hBM-MSCs) leading the way. However, BM-MSCs may not be as optimal as therapeutic cells owing to their low growth potential, invasive harvesting, and high expression of aging-related genes with poor differentiation potential. Consequently, umbilical cord-derived MSCs (hUC-MSCs), which have many excellent features as allogeneic heterologous stem cells, have received considerable attention...
2024: Frontiers in Immunology
#6
JOURNAL ARTICLE
Junhong Cai, Xiaochen Liang, Yuting Sun, Shan Bao
BACKGROUND: Premature ovarian failure (POF), also known as primary ovarian insufficiency, is a common endocrine disease in young women. The emergence of regenerative medicine using stem cells may improve ovarian function and structure, and represents a promising prospect for POF treatment. In his study, we explored the therapeutic effects of human umbilical cord mesenchymal stem cell (HUCMSC) transplantation in a Tibetan miniature pig model of cyclophosphamide (CTX)-induced POF. METHODS: We cultured and identified HUCMSCs, labeled them with DiR iodide red dye, and implanted them into a CTX-induced model of POF in Tibetan miniature pigs...
May 12, 2024: Transplant Immunology
#7
REVIEW
Jing Fu, Wenjie Li, Tengfei Mao, Zaipeng Chen, Lili Lai, Jiachen Lin, Zhiqiang Nie, Yunkai Sun, Yanqin Chen, Qin Zhang, Xigong Li
Spinal cord injury (SCI) can lead to serious functional disorders, which have serious impacts on patients and society. The current traditional treatments of SCI are not effective the injured spinal cord is difficult to repair and regenerate. In recent years, stem cell transplantation for the treatment of SCI has been a hot research topic. Dental pulp stem cells have strong abilities of self-renewal and multi-directional differentiation, and have been applied for tissue engineering and regenerative medicine...
2024: Frontiers in Molecular Biosciences
#8
REVIEW
Maryam Zare Moghaddam, Mohammad Javad Mousavi, Somayeh Ghotloo
Systemic lupus erythematosus (SLE), an autoimmune disease, is among the most prevalent rheumatic autoimmune disorders. It affects autologous connective tissues caused by the breakdown of self-tolerance mechanisms. During the last two decades, stem cell therapy has been increasingly considered as a therapeutic option in various diseases, including parkinson's disease, alzheimer, stroke, spinal cord injury, multiple sclerosis, inflammatory bowel disease, liver disease, diabete, heart disease, bone disease, renal disease, respiratory diseases, and hematological abnormalities such as anemia...
June 2024: Journal of translational autoimmunity
#9
JOURNAL ARTICLE
Yoshiko Atsuta, Helen Baldomero, Daniel Neumann, Anna Sureda, Jakob D DeVos, Minako Iida, Amado Karduss, Duncan Purtill, Alaa M Elhaddad, Nosa G Bazuaye, Carmem Bonfim, Rafael De la Camara, Naeem A Chaudhri, Fabio Ciceri, Cinthya Correa, Cristobal Frutos, Sebastian Galeano, Laurent Garderet, Oscar Gonzalez-Ramella, Raffaella Greco, Nada Hamad, Mette D Hazenberg, Mary M Horowitz, Krzysztof Kalwak, Bor-Sheng Ko, Yoshihisa Kodera, Mickey Bc Koh, Kaiyan Liu, Donal P McLornan, Joon Ho Moon, Benedicte Neven, Shinichiro Okamoto, Marcelo C Pasquini, Jakob R Passweg, Kristjan Paulson, Damiano Rondelli, Annalisa Ruggeri, Adriana Seber, John A Snowden, Alok Srivastava, Jeff Szer, Daniel Weisdorf, Nina Worel, Hildegard Greinix, Wael Saber, Mahmoud Aljurf, Dietger Niederwieser
Promoting access to and excellence in hematopoietic cell transplantation (HCT) by collecting and disseminating data on global HCT activities is one of the principal activities of the Worldwide Network for Blood and Marrow Transplantation, a non-Governmental organization in working relations with the World Health Organization. HCT activities are recorded annually by member societies, national registries and individual centers including indication, donor type (allogeneic/autologous), donor match and stem cell source (bone marrow/peripheral blood stem cells/cord blood)...
May 9, 2024: Haematologica
#10
MULTICENTER STUDY
Danqi Luo, Yuhua Qu, Dao Wang, Benshan Zhang, Ming Sun, Hao Xiong, Jun Lu, Rui Yang, Mingyi Zhao, Haiyan Liu, Hua Jiang
BACKGROUND: For children with severe aplastic anemia, if the first immunosuppressive therapy (IST) fails, it is not recommended to choose a second IST. Therefore, for patients without matched sibling donor (MSD) and matched unrelated donor (MUD), haploidentical hematopoietic stem cell transplantation (Haplo-HSCT) can be chosen as a salvage treatment. This article aims to explore the comparison between upfront Haplo-HSCT and salvage Haplo-HSCT after IST. METHODS: 29 patients received salvage Haplo-HSCT, and 50 patients received upfront Haplo-HSCT...
2024: Frontiers in Immunology
#11
JOURNAL ARTICLE
Nhi T Tran, Tayla R Penny, Kyra Yy Chan, Tanya Tang, Paris C Papagianis, Tara Sepehrizadeh, Lakshmi Nekkanti, Valerie A Zahra, Yen Pham, Tamara Yawno, Ilias Nitsos, Sharmony B Kelly, Alison M Thiel, Michael de Veer, Dhafer M Alahmari, Michael C Fahey, Graham Jenkin, Suzanne L Miller, Robert Galinsky, Graeme R Polglase, Courtney A McDonald
BACKGROUND: Umbilical cord blood (UCB) cells are a promising treatment for preterm brain injury. Access to allogeneic sources of UCB cells offer the potential for early administration to optimise their therapeutic capacities. As preterm infants often require ventilatory support, which can contribute to preterm brain injury, we investigated the efficacy of early UCB cell administration following ventilation to reduce white matter inflammation and injury. METHODS: Preterm fetal sheep (0...
May 8, 2024: Journal of Neuroinflammation
#12
RANDOMIZED CONTROLLED TRIAL
Biqi Zhou, Jia Chen, Tianhui Liu, Yishan Ye, Yanming Zhang, Yiyang Ding, Hong Liu, MingQing Zhu, Xiao Ma, Xiaoli Li, Longfei Zhao, Zhihong Lin, He Huang, Yang Xu, Depei Wu
Coinfusion of unrelated cord blood (UCB) units in haploidentical hematopoietic cell transplantation (haplo-HCT) (haplo-cord HCT) for hematopoietic malignancies showed promising results in previous reports, but the efficiency of haplo-cord HCT in acute myeloid leukemia (AML) still lacks sufficient evidence. This multicenter, randomized, phase 3 trial (ClinicalTrials.gov NCT03719534) aimed to assess the efficacy and safety of haplo-cord HCT in AML patients. A total of 268 eligible patients aged 18-60 years, diagnosed with measurable residual disease in AML (excluding acute promyelocytic leukemia), with available haploidentical donors and suitable for allotransplantation, were randomly allocated (1:1) to receive haplo-cord HCT (n = 134) or haplo-HCT (n = 134)...
May 6, 2024: Signal Transduction and Targeted Therapy
#13
JOURNAL ARTICLE
Qian Yang, Jinfa Huang, Yixuan Liu, Qiqing Mai, Yuan Zhou, Lei Zhou, Lingling Zeng, Kaixian Deng
BACKGROUND: Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) have demonstrated efficacy in repairing uterine scars, although the underlying mechanisms remain unclear. METHODS: Uterine injury was surgically induced in a rat model, followed by immediate transplantation of 5 × 10 ^ 5 hUC-MSCs to each side of the uterus. Uterine morphology was evaluated at days 14 and 30 using HE and Masson staining. Immunohistochemistry assessed macrophage polarization, angiogenesis and endometrial receptivity in the endometrium...
May 4, 2024: Stem cell reviews and reports
#14
JOURNAL ARTICLE
Abdalla Awidi, Abdulrahman Al Shudifat, Nael El Adwan, Mahmoud Alqudah, Fatima Jamali, Fathy Nazer, Halla Sroji, Hady Ahmad, Nahla Al-Quzaa, Hanan Jafar
BACKGROUND AIMS: Spinal cord injury (SCI) affects patients' physical, psychological, and social well-being. Presently, treatment modalities for chronic SCI have restricted clinical effectiveness. Mesenchymal stromal cells (MSCs) demonstrate promise in addressing nervous tissue damage. This single-center, open-label, parallel-group randomized clinical trial aimed to assess the safety and efficacy of intraoperative perilesional administration of expanded autologous bone marrow-derived MSCs (BMMSCs), followed by monthly intrathecal injections, in comparison to monthly intrathecal administration of expanded allogeneic umbilical cord-derived MSCs (UCMSCs) for individuals with chronic SCI...
April 10, 2024: Cytotherapy
#15
Wei-Wei Zhu, Sujing Zhuang, Zhe Yu, Xin Li, Tian-Jie Han, Yue Ma, Li-Jun Li, Zhi-Rui Zhao
INTRODUCTION: At present, cyclosporine (CsA) is the first-line treatment for Pure Red Cell Aplasia (PRCA), but CsA administration can be associated with a number of side effects due to its high toxicity. Therefore, it is urgent to explore a safe and effective treatment for elderly patients who cannot be treated with conventional doses of CsA, especially those with multiple complications. Allogeneic Stem Cell Transplantation (ASCT) for PRCA is a promising treatment, but reports of using umbilical cord blood (UCB) are very rare...
May 2, 2024: Current Stem Cell Research & Therapy
#16
JOURNAL ARTICLE
Tatsuya Konishi, Kensuke Matsuda, Hidehiro Itonaga, Noriko Doki, Tetsuya Nishida, Ken-Ichi Matsuoka, Takashi Ikeda, Yoshinobu Kanda, Takahiro Fukuda, Junya Kanda, Hirohisa Nakamae, Kazunori Imada, Yasunori Ueda, Tatsuo Ichinohe, Yoshiko Atsuta, Ken Ishiyama
Cytomegalovirus (CMV) reactivation is a prominent complication associated with adverse outcomes in allogeneic hematopoietic stem cell transplantation (HSCT). However, CMV reactivation after allogeneic HSCT may be associated with a lower incidence of relapse in some hematological malignancies. This study analyzed the Japanese registry data from 1,082 patients with myelodysplastic syndrome (MDS) who underwent their first allogeneic HSCT and survived for 100 days after transplantation without graft failure or disease relapse to investigate this association...
April 30, 2024: Transplantation and cellular therapy
#17
JOURNAL ARTICLE
Shafiqa Naeem Rajput, Bushra Kiran Naeem, Anwar Ali, Asmat Salim, Irfan Khan
BACKGROUND: Stem cells are undifferentiated cells that possess the potential for self-renewal with the capacity to differentiate into multiple lineages. In humans, their limited numbers pose a challenge in fulfilling the necessary demands for the regeneration and repair of damaged tissues or organs. Studies suggested that mesenchymal stem cells (MSCs), necessary for repair and regeneration via transplantation, require doses ranging from 10 to 400 million cells. Furthermore, the limited expansion of MSCs restricts their therapeutic application...
April 26, 2024: World Journal of Stem Cells
#18
JOURNAL ARTICLE
Zhong Zhang, Jianqiang Ji, Xuan Pan, Chuanjie Niu, Liwei Xu, Wenrui Lei, Zifeng Zeng, Qiong Chen, Qingbao Peng, Shaoyi Zheng, Jun Lu, Pengyu Zhou
BACKGROUND: This study aimed to investigate the cardioprotective effect of exosomes derived from human umbilical cord mesenchymal stem cells on donation after circulatory death (DCD) hearts preserved with normothermic ex vivo heart perfusion (EVHP) in a rat heart transplantation model. METHODS: Thirty-two male Lewis rats were divided into 2 groups: the control group and the exosome group. The donor-heart rats were subjected to the DCD procedure by suffering a 15-min warm ischemia injury, subsequently preserved with EVHP for 90 min, and then transplanted into recipients via abdominal heterotopic heart transplantation...
April 30, 2024: Transplantation
#19
REVIEW
Ju Deng, Yanhong Tan, Zhifang Xu, Hongwei Wang
Hematopoietic stem cells (HSCs) are an ideal source for the treatment of many hematological diseases and malignancies, as well as diseases of other systems, because of their two important features, self-renewal and multipotential differentiation, which have the ability to rebuild the blood system and immune system of the body. However, so far, the insufficient number of available HSCs, whether from bone marrow (BM), mobilized peripheral blood or umbilical cord blood, is still the main restricting factor for the clinical application...
April 30, 2024: Annals of Hematology
#20
JOURNAL ARTICLE
Francesca Merighi, Sara De Vincentiis, Marco Onorati, Vittoria Raffa
Resolutive cures for spinal cord injuries (SCIs) are still lacking, due to the complex pathophysiology. One of the most promising regenerative approaches is based on stem cell transplantation to replace lost tissue and promote functional recovery. This approach should be further explored better in vitro and ex vivo for safety and efficacy before proceeding with more expensive and time-consuming animal testing. In this work, we show the establishment of a long-term platform based on mouse spinal cord (SC) organotypic slices transplanted with human neural stem cells to test cellular replacement therapies for SCIs...
April 12, 2024: Journal of Visualized Experiments: JoVE
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
